title: Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
authors.affiliation: Princess Margaret Phase II Consortium , Toronto, Ontario , Canada.
authors.forename: Karen W L
authors.initials: KW
authors.lastname: Yee
authors.forename: John M
authors.initials: JM
authors.lastname: Storring
authors.forename: Rena
authors.initials: R
authors.lastname: Buckstein
authors.forename: Richard A
authors.initials: RA
authors.lastname: Wells
authors.forename: Anargyros
authors.initials: A
authors.lastname: Xenocostas
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Kovacs
authors.forename: Kang
authors.initials: K
authors.lastname: Howson-Jan
authors.forename: Eunice S
authors.initials: ES
authors.lastname: Wang
authors.forename: Kristina
authors.initials: K
authors.lastname: Battista
authors.forename: Lisa
authors.initials: L
authors.lastname: Wang
authors.forename: Amit M
authors.initials: AM
authors.lastname: Oza
authors.forename: S Percy
authors.initials: SP
authors.lastname: Ivy
authors.forename: Andre C
authors.initials: AC
authors.lastname: Schuh
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000473:pathology; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D000077210:Sunitinib; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib